Cargando…

Incidence of Bloodstream Infection in Patients with Pulmonary Hypertension under Intravenous Epoprostenol or Iloprost—A Multicentre, Retrospective Study

Intravenous synthetic prostacyclin analogs (iPCAs), such as epoprostenol, treprostinil and iloprost have been widely used for the treatment of pulmonary arterial hypertension (PAH). Despite having good outcomes, continuous infusion of iPCAs has been associated with some adverse effects. Bloodstream...

Descripción completa

Detalles Bibliográficos
Autores principales:	Camara, Raquel Paulinetti, Coelho, Francisco das Neves, Cruz-Martins, Natália, Marques-Alves, Patrícia, Castro, Graça, Baptista, Rui, Ferreira, Filipa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094981/ https://www.ncbi.nlm.nih.gov/pubmed/37047407 http://dx.doi.org/10.3390/ijms24076434

Ejemplares similares

The impact of nebulized epoprostenol and iloprost on hemoglobin oxygen affinity: an ex vivo experiment
por: Woyke, Simon, et al.
Publicado: (2022)

Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy
por: Timofeev, Julia, et al.
Publicado: (2013)

Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report
por: Alexandre, André, et al.
Publicado: (2023)

Epoprostenol: Flushing or Erythroderma?
por: Martínez-Martínez, María Luisa, et al.
Publicado: (2013)

Epoprostenol Exposure During Pregnancy
por: Naoum, Emily E., et al.
Publicado: (2023)

Rapid Initiation of Intravenous Epoprostenol Infusion Is the Favored Option in Patients with Advanced Pulmonary Arterial Hypertension
por: Kimura, Mai, et al.
Publicado: (2015)

Cardiovascular Effect of Epoprostenol and Intravenous Cardiac Drugs for Acute Heart Failure on Canine Pulmonary Hypertension
por: Yuchi, Yunosuke, et al.
Publicado: (2023)

Epoprostenol: Exacerbation of thrombocytopenia : case report
Publicado: (2021)

Stress Cardiomyopathy Precipitated by Withdrawal of Epoprostenol
por: Gionfriddo, William J., et al.
Publicado: (2020)

Successful treatment of jellyfish sting-induced severe digital ischemia with intravenous iloprost infusion
por: Lo, Arthur H., et al.
Publicado: (2016)

Epoprostenol sodium for treatment of pulmonary arterial hypertension
por: Saito, Yukihiro, et al.
Publicado: (2015)

Use of Epoprostenol in the Treatment of Pulmonary Arterial Hypertension
por: Mohammadi, Asma, et al.
Publicado: (2021)

Alteplase/epoprostenol: Lack of efficacy: case report
Publicado: (2022)

Epoprostenol‐associated ascites in pulmonary arterial hypertension
por: Schoenberg, Noah C., et al.
Publicado: (2022)

Hyperbaric Oxygen Therapy with Iloprost Improves Digit Salvage in Severe Frostbite Compared to Iloprost Alone
por: Magnan, Marie-Anne, et al.
Publicado: (2021)

Inhaled iloprost for the control of pulmonary hypertension
por: Krug, Sabine, et al.
Publicado: (2009)

Iloprost for COVID-19-related vasculopathy
por: Moezinia, Carine J, et al.
Publicado: (2020)

An Adolescent Patient With Idiopathic Pulmonary Arterial Hypertension Weaned Off Intravenous Epoprostenol Following Treatment With Selexipag: A Case Report
por: Chida-Nagai, Ayako, et al.
Publicado: (2022)

Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy
por: Knudsen, Lars, et al.
Publicado: (2011)

Microbial challenge test of a novel epoprostenol sodium formulation
por: Bandilla, Dirk, et al.
Publicado: (2017)

Successful use of inhaled epoprostenol as rescue therapy for pediatric ARDS
por: Urich, Alissa, et al.
Publicado: (2020)

Goiter in a Patient with Pulmonary Arterial Hypertension Treated with Epoprostenol
por: Abughazaleh, Shaadi, et al.
Publicado: (2020)

Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19
por: Sonti, Rajiv, et al.
Publicado: (2020)

Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
por: Sitbon, Olivier, et al.
Publicado: (2017)

Nitric oxide versus epoprostenol for refractory hypoxemia in Covid-19
por: Poonam, Pai B. H., et al.
Publicado: (2022)

PSAT054 Isolated ACTH Deficiency in a Patient on Epoprostenol
por: Riordan, Marianne, et al.
Publicado: (2022)

A Case of Giant Goiter Associated with Airway Stenosis Caused by Long-Term Intravenous Epoprostenol Therapy for Idiopathic Pulmonary Arterial Hypertension
por: Nishiura, Kazuto, et al.
Publicado: (2023)

Iloprost modulates the immune response in systemic sclerosis
por: D'Amelio, Patrizia, et al.
Publicado: (2010)

Inhaled iloprost for the treatment of patient with Fontan circulation
por: Kim, Yong Hyun, et al.
Publicado: (2014)

Effectiveness of Iloprost in the Treatment of Bone Marrow Edema
por: Tosun, Hacı Bayram, et al.
Publicado: (2020)

Iloprost in COVID-19: The Rationale of Therapeutic Benefit
por: Faggioli, Paola Maria, et al.
Publicado: (2021)

Iloprost for the treatment of frostbite: a scoping review
por: Gauthier, Josianne, et al.
Publicado: (2023)

Inhaled iloprost as third add-on therapy in idiopathic pulmonary arterial hypertension
por: Fernandes, Caio J.C.S., et al.
Publicado: (2021)

Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study
por: Frantz, Robert P., et al.
Publicado: (2015)

Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
por: Calcaianu, George, et al.
Publicado: (2017)

Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension
por: Abston, Eric, et al.
Publicado: (2020)

HIGH-FLOW NASAL CANULA AND INHALED EPOPROSTENOL RESPONSE IN COVID-19
por: KHURANA, NEHARIKA, et al.
Publicado: (2022)

Use of fluorescence to visualize response to iloprost treatment for frostbite
por: MacLennan, Mira, et al.
Publicado: (2021)

Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery
por: Guan, Zheng, et al.
Publicado: (2018)

Occult catheter rupture causing episodic symptoms in a patient treated with epoprostenol
por: LeVarge, Barbara L., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lvig7tu7datkvkipntohjrjsgb